---
title: "Adding TRT to a GLP-1 brand without splitting your funnel"
description: "Hormone therapy attracts a different patient with a longer lifetime value. When category expansion works, when it dilutes the brand, and how to sequence it."
canonical: "https://cuvo.co/blog/trt-category-expansion"
last-updated: "May 20, 2026"
---
# Adding TRT to a GLP-1 brand without splitting your funnel

By Priya Raman, Director of Partner Growth. Published May 20, 2026. Growth.

Hormone therapy brings in a different patient than a weight-loss program does: typically older, male, and on a therapy built to continue once it is stable rather than run to a goal. That patient can carry a longer treatment relationship, but only for a brand that has earned the right to expand. Here is when TRT strengthens a GLP-1 brand, when it blurs it, and how to sequence the launch.

Most brands that reach a certain size on a GLP-1 program ask the same question: what is the second category? For a men's-oriented brand, testosterone replacement therapy is the common answer. It reaches a different patient, it tends to run longer, and Cuvo already operates the clinical, pharmacy, and compliance machinery it requires. The hard part is not the medicine. It is deciding whether your brand can hold two promises at once without confusing the first audience you paid to earn.

**TRT at a glance: the clinical and regulatory picture**
- Drug schedule: Testosterone is Schedule III
- Visit format: Interactive audio-video required
- In-person visit: Not required through Dec 31, 2026
- Prescriber: DEA-registered, state-licensed provider
- Core labs: Total testosterone, hematocrit, PSA
- Monitoring cadence: Baseline, 3 to 6 months, then annually
- Therapy horizon: Ongoing once titrated and stable
- On Cuvo: Every plan, no vertical restriction

## 01. The patient on the other side of the ad

The GLP-1 patient and the TRT patient are rarely the same person. Published real-world studies of telehealth weight-loss cohorts describe a population that skews heavily female, on the order of 70 to 80 percent, with a mean age in the mid-40s. Testosterone therapy inverts that: published analyses of US prescribing patterns place the majority of testosterone prescriptions in men aged 40 to 64, with the 45-to-64 band alone accounting for roughly 60 percent. One category is mostly women in their forties; the other is mostly men in the same decade and older.

That gap is not a reason to avoid expansion. Audience overlap is real, and men do arrive through a weight-loss funnel and stay for hormone care. But TRT is rarely a simple upsell to your existing list. It is closer to a deliberate second audience, and operators who treat it that way launch it more cleanly than the ones who assume their GLP-1 buyers will convert.

## 02. What a longer treatment relationship actually means

The phrase you will hear is longer lifetime value. Be precise about it: it is not a promised dollar figure, and Cuvo makes no earnings claims. Operationally it means two things, longer treatment durations and a steadier refill cadence.

Endocrinology literature frames testosterone therapy as ongoing maintenance once a patient is titrated to a stable level. Unlike a weight-loss course, which has a target and a natural taper conversation, hormone therapy has no built-in endpoint, so a stable patient is usually a continuing one. Real-world persistence is more mixed, and worth reporting honestly: published treatment-pattern studies show many patients lapse in the first months. The gap is usually follow-through, not clinical need, which is exactly why monitoring and support move the number. A category that rewards operational rhythm rewards a platform built to keep patients seen and refilled on time.

## 03. The clinical difference: TRT is a monitored therapy

This is the operational line GLP-1 operators most often underestimate. A testosterone program is a lab-monitored therapy from the first visit. Endocrine Society guidelines call for a baseline total testosterone and hematocrit, a PSA for men over 40, a recheck at three to six months, and ongoing monitoring on a defined schedule, typically annually. A hematocrit that climbs too high, or a PSA change past a defined threshold, changes the clinical plan. None of that exists in a standalone GLP-1 program the same way.

Here Cuvo's infrastructure carries the difference, not your team. Lab ordering runs through Labcorp and Quest inside the same platform your weight-loss patients already use, so the baseline and follow-up panels a testosterone patient needs are ordered, tracked, and returned to the treating provider without your operators standing up a lab program from scratch. The monitoring cadence is a clinical requirement; on Cuvo it is a platform feature.

## 04. The regulatory difference: testosterone is Schedule III

GLP-1s are not controlled substances. Semaglutide and tirzepatide can be evaluated through a lower-friction, asynchronous intake where state law allows. Testosterone cannot, because it sits on Schedule III of the Controlled Substances Act, and that single fact reshapes the intake.

Under the DEA and HHS fourth temporary rule, issued December 31, 2025, a DEA-registered practitioner may prescribe Schedule II through V controlled substances, testosterone included, via telemedicine with no initial in-person visit, through December 31, 2026. The flexibility is real, and it is conditional. Every controlled-substance prescription must meet all five conditions in paragraph (c): a legitimate medical purpose; a practitioner acting in the usual course of professional practice; an evaluation conducted over an interactive audio-video system, not chat or a questionnaire alone; a practitioner holding a DEA registration for that class of substance; and compliance with all other DEA regulations, including 21 CFR part 1306.

The operational consequence is one line: a TRT patient needs a real-time video visit with a DEA-registered, state-licensed provider, where a GLP-1 patient may not. Your two funnels diverge at exactly that point, and the divergence is a compliance requirement, not a design choice.

> **The division of labor does not change** Adding TRT does not hand your team a clinical program to run. Cuvo runs the providers, the pharmacy, the lab ordering, and the compliance structure for hormone therapy exactly as it does for weight loss, and every prescribing decision stays at the treating provider's sole discretion. The operator's job in a category expansion is the brand and audience decision: who you speak to, what you promise, and how the two paths coexist. Cuvo runs the clinic; you run the brand.

## 05. When expansion works, and when it dilutes

Category expansion is not a maturity milestone every brand should hit on a timeline. It works under specific conditions and backfires under others.

**When adding TRT dilutes the brand**
- The GLP-1 program has not found its own rhythm, so a second category competes for attention it cannot spare
- The brand promise is vague enough that a second category only makes it vaguer
- Ad budget splits across two categories before the first has traction, starving both
- Positioning whiplash: one audience pitched two unrelated outcomes with no connective logic
- No one owns the second audience, so TRT becomes a menu item rather than a funnel

**When adding TRT strengthens the brand**
- An established GLP-1 program with a steady operational rhythm and retention past the early months
- Audience overlap you can name, or a deliberate second audience you are ready to acquire
- A brand promise wide enough to hold both, or distinct paths that each carry their own promise
- Budget to fund the second category as its own line, not a reallocation that weakens the first
- Clear ownership of the TRT funnel end to end, from creative to intake

## 06. Sequence it: split the funnel at intake, not the brand

The mechanical question is where the two categories separate. The answer that holds up is: as late as possible on the brand, as early as necessary in the flow. One brand, one storefront, two clearly separated paths.

1. Launch TRT only after the GLP-1 program has a stable operational rhythm and retention you can measure
2. Keep one brand and one storefront; do not spin up a second identity for the second category
3. Give each category its own landing path and intake flow, with messaging specific to that patient and outcome
4. Fund the TRT launch as its own marketing line so it does not drain the GLP-1 budget
5. Route TRT intake to a real-time video visit by design, and let GLP-1 keep its lower-friction path
6. Let the funnel split at intake, where the patient's needs and the regulatory requirements genuinely differ, not at the brand, where a split just confuses the audience
7. Assign clear ownership of the TRT audience so it is acquired deliberately, not left as a passive add-on

## 07. What Cuvo already runs

For a brand already operating on Cuvo, the clinical lift of adding TRT is close to zero, because the category is not a new integration. TRT is available on every plan with no vertical restriction. The same provider network that sees your weight-loss patients includes DEA-registered, state-licensed providers who prescribe testosterone; the same pharmacy fulfills it; the same platform orders the labs through Labcorp and Quest and enforces the audio-video visit the schedule requires. Prescriptions remain at the treating provider's sole discretion, as they do in every category, and the compliance structure of audio-video consults, DEA-registered providers, and lab ordering is already in place.

What is left is the part only the operator can do: decide whether the brand should carry a second promise, name the audience it is for, and sequence the launch so the first category keeps its momentum. That is a marketing and positioning decision, and it is the right one to spend your judgment on, because the clinical, pharmacy, and regulatory work underneath it is already running.

## Frequently asked questions

**Q: Does TRT require different providers than a GLP-1 program?**

A: No. The same 50-state provider network handles both. The difference is that a testosterone prescriber must be DEA-registered for the relevant schedule and licensed in the patient's state, a credential Cuvo verifies before any controlled-substance visit is booked.

**Q: Why does TRT need a video visit when a GLP-1 patient can complete an async intake?**

A: Because testosterone is a Schedule III controlled substance and a GLP-1 is not. Under the DEA's fourth temporary rule, a controlled-substance prescription issued via telemedicine must come from an interactive audio-video evaluation, not a questionnaire or chat alone, through December 31, 2026. Standalone GLP-1s were never controlled substances, so the visit format follows the scheduling of the drug, not a brand preference. On Cuvo, providers conduct the audio-video visit for TRT and prescribe through EPCS, while GLP-1 intake stays asynchronous.

**Q: Should the two categories share one storefront and brand?**

A: In most cases, yes. Keep one brand and one storefront, and let the categories separate at intake through distinct landing paths and category-specific messaging. Splitting the brand itself usually adds cost and confusion without a matching benefit, while splitting the funnel at intake matches where the patient's needs and the regulatory requirements actually diverge. Cuvo runs both categories behind one branded storefront with category-specific intake flows switched on per program.

**Q: How soon after launch should a brand add TRT?**

A: There is no fixed number, and adding it too early is the more common mistake. Expansion tends to work once the GLP-1 program has its own operational rhythm and measurable retention past the early months, and once there is budget to fund the second category as its own line rather than a reallocation that weakens the first. On Cuvo, TRT is available on every plan from day one, so adding it is a timing decision the brand makes with its own retention data.

**Keep reading**
- [DEA extends telemedicine flexibilities through 2026](/blog/dea-telemedicine-flexibilities-2026): The full rule behind TRT's audio-video requirement
- [Pricing a weight-loss subscription patients keep for a year](/blog/pricing-telehealth-subscriptions): Retention mechanics that decide when you are ready to expand
- [Provider network vs. hiring your own clinicians for telehealth](/blog/provider-network-vs-hiring-your-own-clinicians): Which clinical model fits hormone therapy and TRT
- [Compare Cuvo to other platforms](/compare): Where TRT sits across plans and providers

*Regulatory and medical disclaimer: This article is for informational purposes only and is not legal or medical advice. All prescribing decisions rest with the treating licensed provider, who prescribes only when clinically appropriate. The regulatory conditions described reflect the DEA and HHS fourth temporary rule in effect through December 31, 2026; that rule is temporary and may change. Brands operating on Cuvo remain responsible for complying with all applicable federal and state laws. Consult qualified healthcare and legal counsel for guidance on your situation.*

Canonical page: https://cuvo.co/blog/trt-category-expansion